Chiba Univ. Finds Dropout Rates of 60-80% in Secondary Endpoints, Raps VART Study as “Absolutely Unreliable”

A university probe has discovered that patient dropout rates for secondary endpoints in a Diovan (valsartan) clinical trial stood at a hefty 60-80% three years after their enrollments - a finding that shatters the credibility of significantly higher efficacy claimed...read more